Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 17/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.35 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.35 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3464730 | 0.85 | HSP90AA1 (0.40) | HSP90AA1HSP90AB1RIPK2 | |
| SCHEMBL3464443 | 0.84 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1ERBB2HSP90B1TRAP1 | |
| SCHEMBL3464733 | 0.84 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1ERBB2 | |
| SCHEMBL3465443 | 0.82 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1 | |
| SCHEMBL3465317 | 0.82 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1RIPK2 | |
| SCHEMBL3465405 | 0.82 | HSP90AA1 (0.35) | HSP90AA1HSP90AB1RIPK2 | |
| SCHEMBL3465166 | 0.75 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1 | |
| SCHEMBL3463800 | 0.72 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1 | |
| SCHEMBL3465260 | 0.70 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1ERBB2HSP90B1TRAP1 | |
| SCHEMBL3465450 | 0.70 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240656-A1 | COMPOUNDS AS HSP90 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2010-09-23 | — | — | US | claimed |
| EP-2183221-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | Crystax Pharmaceuticals S.L. (ES) | 2010-05-12 | — | — | EP | claimed |
| WO-2009007399-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-01-15 | — | — | WO | claimed |
| US-20100240656-A1 | COMPOUNDS AS HSP90 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2010-09-23 | — | — | US | disclosed |
| US-20100240656-A1 | COMPOUNDS AS HSP90 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2010-09-23 | — | — | US | disclosed |
| US-20100240656-A1 | COMPOUNDS AS HSP90 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2010-09-23 | — | — | US | disclosed |
| EP-2183221-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | Crystax Pharmaceuticals S.L. (ES) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009007399-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007399-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240656-A1 | COMPOUNDS AS HSP90 INHIBITORS | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885OGA 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.